- Home
- NATR vs MNPR Comparison
NATR vs MNPR Comparison
Compare NATR & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NATR
- MNPR
- Stock Information
- Founded
- NATR 1972
- MNPR 2014
- Country
- NATR United States
- MNPR United States
- Employees
- NATR N/A
- MNPR N/A
- Industry
- NATR Biotechnology: Pharmaceutical Preparations
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- NATR Health Care
- MNPR Health Care
- Exchange
- NATR Nasdaq
- MNPR Nasdaq
- Market Cap
- NATR 271.6M
- MNPR 248.8M
- IPO Year
- NATR N/A
- MNPR 2019
- Fundamental
- Price
- NATR $16.54
- MNPR $35.71
- Analyst Decision
- NATR Strong Buy
- MNPR Strong Buy
- Analyst Count
- NATR 2
- MNPR 7
- Target Price
- NATR $20.50
- MNPR $62.00
- AVG Volume (30 Days)
- NATR 86.7K
- MNPR 20.7K
- Earning Date
- NATR 07-31-2025
- MNPR 08-12-2025
- Dividend Yield
- NATR N/A
- MNPR N/A
- EPS Growth
- NATR N/A
- MNPR N/A
- EPS
- NATR 0.75
- MNPR N/A
- Revenue
- NATR $460,818,000.00
- MNPR N/A
- Revenue This Year
- NATR $3.08
- MNPR N/A
- Revenue Next Year
- NATR $2.41
- MNPR N/A
- P/E Ratio
- NATR $22.09
- MNPR N/A
- Revenue Growth
- NATR 4.33
- MNPR N/A
- 52 Week Low
- NATR $11.01
- MNPR $2.15
- 52 Week High
- NATR $18.06
- MNPR $54.30
- Technical
- Relative Strength Index (RSI)
- NATR 63.70
- MNPR 43.81
- Support Level
- NATR $15.16
- MNPR $30.51
- Resistance Level
- NATR $16.79
- MNPR $36.51
- Average True Range (ATR)
- NATR 0.55
- MNPR 3.33
- MACD
- NATR 0.16
- MNPR -0.95
- Stochastic Oscillator
- NATR 91.32
- MNPR 37.55
About NATR Nature's Sunshine Products Inc.
Natures Sunshine Products Inc is a natural health and wellness company, predominantly engaged in the manufacturing and selling of nutritional and personal care products. It offers products related to Weight management, General health, Cardiovascular, Digestive, Immune, and Personal care. The company operates in four segments namely, Asia which is also its key revenue generating market, Europe, North America, Latin America, and Other.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.